Skip to main content
Clinical Trials/NCT05428358
NCT05428358
Recruiting
Not Applicable

Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery (MAGIPAC): A Randomized Clinical Trial.

University of Aarhus3 sites in 1 country200 target enrollmentAugust 30, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pancreatic Cancer
Sponsor
University of Aarhus
Enrollment
200
Locations
3
Primary Endpoint
Change in treatment strategy
Status
Recruiting
Last Updated
5 months ago

Overview

Brief Summary

The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.

Detailed Description

The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients. We will conduct a nationwide, prospective clinical trial to examine the incremental value of using MRI for identification of liver metastases in pancreatic cancer patients.

Registry
clinicaltrials.gov
Start Date
August 30, 2022
End Date
December 1, 2028
Last Updated
5 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Change in treatment strategy

Time Frame: 1 week

Change in treatment strategy from intended curative resection to other treatment based on MRI scan

Secondary Outcomes

  • Surgery(1 month)
  • Intraoperatively detected liver metastases(1 month)
  • Liver metastases(1 week)
  • Overall survival (1-year)(1 year)
  • Resection(1 month)
  • Overall survival (3-year)(3 years)
  • Recurrence-free survival(3 years)
  • Healthcare costs(3 years)

Study Sites (3)

Loading locations...

Similar Trials